Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review.

Published on Nov 1, 2009in The British journal of psychiatry. Supplement
· DOI :10.1192/BJP.195.52.S13
David Taylor168
Estimated H-index: 168
Sources
Abstract
Background Depot antipsychotics are widely used in clinical practice. Long-acting formulations of second-generation antipsychotics are now being developed and introduced. Aims To review the pharmacology, pharmacokinetics and adverse effect profiles of currently available antipsychotic long-acting injections (LAIs). Method The psychopharmacological properties of first- and second-generation antipsychotic LAIs are reviewed using data available up to October 2008. Results First-generation antipsychotic (FGA) LAIs are associated with a high rate of acute and chronic movement disorders. Risperidone LAI is better tolerated in this respect, but is associated with hyperprolactinaemia and weight gain. Olanzapine LAI causes weight gain and other metabolic effects but appears not to be associated with an important incidence of movement disorders. Conclusions Dosing of LAIs is complicated by delayed release of drug, changes in plasma levels without change in dose, and by the lack of data establishing clear dose requirements. All LAIs offer the prospect of assured adherence (although patients may still default on treatment) but their use is complicated by adverse effects, complex pharmacokinetics and confusion over dose–response relationships.
Figures & Tables
Download
📖 Papers frequently viewed together
201118.11American Journal of Psychiatry
6 Authors (Mark Taylor)
20114.94Schizophrenia Research
6 Authors (Claudia Leucht, ..., Stefan Leucht)
20019.32British Journal of Psychiatry
4 Authors (Clive E Adams, ..., Anthony S. David)
References83
Newest
Background Antipsychotic long-acting injections (LAIs) are often used in an attempt to improve medication adherence in people with schizophrenia. Aims To compare first-generation antipsychotic long-acting injections (FGA–LAIs) with first- and second-generation oral antipsychotics in terms of clinical outcome. Method Systematic literature review. Results A meta-analysis of randomised controlled trials (RCTs) showed no difference in relapse or tolerability between oral antipsychotics and FGA–LAIs ...
Source
Source
May 11, 2008·The Journal of Clinical Psychiatry4.38
#1John Lauriello (UNM: University of New Mexico)H-Index: 46
#2Tim LambertH-Index: 30
Last. David McDonnellH-Index: 15
view all 6 authors...
Objective: To examine the efficacy and tolerability of a new injectable formulation of olanzapine, olanzapine long-acting injection (LAI), relative to placebo for treatment of acutely ill patients with schizophrenia. Method: Patients with DSM-IV or DSM-IV-TR schizophrenia in this 8-week, double-blind study were randomly assigned to receive 210 mg/2 weeks, 300 mg/2 weeks, or 405 mg/4 weeks of olanzapine LAI or placebo/2 weeks. No oral antipsychotic supplementation was permitted. The primary effic...
Source
Jan 1, 2008·Neuropsychopharmacology7.86
#4Marc Laruelle (NewYork–Presbyterian Hospital)H-Index: 25
D 2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia
Source
This subgroup analysis of the 6-month, open-label Switch to Risperidone Microspheres (StoRMi) trial evaluated long-term safety and efficacy of a direct conversion to risperidone long-acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot antipsychotic. Study outcomes included adverse events, movement disorder severity, psychiatric symptoms, functional ability, quality of life and patient satisfaction. Change in the Positive and Negative Syndrome Sc...
Source
Aug 23, 2007·Acta Psychiatrica Scandinavica6.39
#1U. G. AhlforsH-Index: 7
#2S. J. DenckerH-Index: 5
Last. J. RemvigH-Index: 1
view all 4 authors...
The clinical properties of clopenthixol decaonate has been investigated versus perphenazine enanthate in a double-blind clinical multicentre trial including 14 psychiatric hospitals in Finland, Sweden, Norway, and Denmark.
Source
Aug 23, 2007·Acta Psychiatrica Scandinavica6.39
#1Jrgensen A (Lundbeck)H-Index: 1
#2Overø Kf (Lundbeck)H-Index: 1
Serum concentrations of clopenthixol and flupenthixol have been determined during a four weeks dosage interval in patients trelated with intramuscular injections of clopenthixol decanoate or flupenthixol palmitate in Viscoleo®. Maximal drug levels were attained by the end of the first week after injection of either preparation. A period of exponential decline was then recorded. The half-lives were estimated to 19 days for clopenthixol and 17 days for flupenthixol. These half-lives most likely re...
Source
Aug 15, 2007·The Journal of Clinical Psychiatry4.38
#1Ya-Mei Bai (Taipei Veterans General Hospital)H-Index: 50
#2Tzu-Ting ChenH-Index: 17
Last. Wen Kuo LinH-Index: 3
view all 7 authors...
Objective: Previous studies showed clinical benefit of risperidone long-acting injection in the treatment of schizophrenia. However, the equivalent switching dose from oral risperidone to risperidone long-acting injection was still in debate. This study, conducted among hospitalized patients, included a long-enough study period and optimal control of drug compliance to test the equivalent switching dose. Method: Fifty symptomatic, stable hospitalized patients with DSM-IV schizophrenia were rando...
Source
Aug 1, 2007·British Journal of Psychiatry9.32
#1Nicholas A Keks (Mental Health Research Institute)H-Index: 27
#2Michael InghamH-Index: 1
Last. Keith KarcherH-Index: 15
view all 4 authors...
Background The efficacy and safety of long-acting injectable risperidone have not been compared with those of an oral atypical antipsychotic. Aims To compare long-acting risperidone and oral olanzapine in 377 patients with DSM–IV schizophrenia or schizoaffective disorder. Method Patients were randomised to receive long-acting risperidone (25 mg or 50 mg every 14 days) or olanzapine (5–20 mg/day). Results In the 13-week phase, long-acting risperidone was at least as effective as (not inferior to)...
Source
Jul 1, 2007·Acta Psychiatrica Scandinavica6.39
#1O. S. NiazH-Index: 1
#2Peter M. Haddad (University of Manchester)H-Index: 52
Objective: To report the use of risperidone long-acting injection (RLAI) in a UK psychiatric service. Method: Retrospective case note review of all patients prescribed RLAI over a 35-month period. In the mirror-image analysis patients initiated on RLAI as in-patients had the index admission attributed to previous treatment. Results: Patients prescribed RLAI had significantly higher baseline rates of drug misuse, alcohol misuse, unemployment and forensic markers than control patients prescribed o...
Source
123456789
Cited By87
Newest
Source
Mar 15, 2021·Cns Spectrums3.79
#1Leslie Citrome (NYMC: New York Medical College)H-Index: 72
Current guidelines for the treatment of patients with schizophrenia advocate that patients receive treatment with a long-acting injectable (LAI) antipsychotic medication if they prefer such treatment or if they have a history of poor or uncertain adherence. Available LAI formulations in the United States include first-generation antipsychotics (fluphenazine decanoate and haloperidol decanoate), risperidone/paliperidone containing products (risperidone microspheres, paliperidone palmitate, and ri...
Source
Feb 8, 2021·CNS Neuroscience & Therapeutics5.24
#1Michael Ming Cheuk Wong (Queen Mary Hospital)H-Index: 1
#2Albert K. K. Chung (Queen Mary Hospital)H-Index: 4
Last. Ki Yan MakH-Index: 1
view all 11 authors...
AIMS There is increasing evidence showing the importance of long-acting injectable antipsychotics in the management of schizophrenia, especially in terms of improving patient medication compliance. A panel of experienced clinicians in Hong Kong mapped out a set of consensus statements with an aim to facilitate the understanding and use of long-acting injectable antipsychotics among local physicians. METHODS Eight discussion areas regarding long-acting injectable antipsychotics were selected by t...
Source
Jan 1, 2021·Journal of Psychiatric Research4.79
#1Taro Kishi (Fujita Health University)H-Index: 38
#2Kenji Sakuma (Fujita Health University)H-Index: 6
Last. Nakao Iwata (Fujita Health University)H-Index: 75
view all 4 authors...
Abstract We investigated the association between discontinuation due to withdrawal of consent (DWC) in schizophrenia trials and the use of long-acting injectable antipsychotics (LAI-APs). In two categorical meta-analyses of randomized controlled trials, we compared DWC: individual and pooled LAI-APs vs. (1) placebo and (2) oral antipsychotics (OAPs). We also performed conducted a single-group meta-analysis to calculate the average DWC and a meta-regression analysis to examine the association bet...
Source
Sep 1, 2020·Psiquiatría Biológica
#1Carlos López-Jaramillo (UdeA: University of Antioquia)H-Index: 22
#2Ana M. Díaz-Zuluaga (UdeA: University of Antioquia)H-Index: 8
Last. Gerhard GründerH-Index: 29
view all 41 authors...
Resumen Objetivo La Monitorizacion Terapeutica de Drogas (llamada en ingles TDM: therapeutic drug monitoring) combina la cuantificacion de las concentraciones de medicamentos en la sangre, la interpretacion farmacologica y las directrices de tratamiento. La TDM introduce una herramienta de medicina de precision en una ipoca de gran conciencia de la necesidad de tratamientos personalizados en neurologia y psiquiatria. Las indicaciones claras de la TDM incluyen la ausencia de respuesta clinica en ...
Source
#1Robert McCutcheonH-Index: 2
#2Stephen J. Kaar
Last. Oliver HowesH-Index: 2
view all 3 authors...
Source
Jan 1, 2020·American Journal of Geriatric Psychiatry4.11
#1Ching-Hua Lin (KMU: Kaohsiung Medical University)H-Index: 15
#2Feng-Chua ChenH-Index: 2
Last. Chun-Chi HsuH-Index: 2
view all 4 authors...
Abstract Objective The effectiveness of long-acting injectable antipsychotics (LAIs) in elderly patients with schizophrenia remains unclear. This study aimed to compare the effect of LAIs with oral antipsychotics (OAPs) on time to rehospitalization within one year of discharge in this population. Other factors potentially associated with time to rehospitalization and trends in LAI prescription rates during the study period were also investigated. Methods Patients over 60 years of age with schizo...
Source
Sep 1, 2019·European Neuropsychopharmacology4.60
#1Sung Woo JooH-Index: 6
#2Seung-Hyun Shon (UOU: University of Ulsan)H-Index: 6
Last. Jungsun Lee (UOU: University of Ulsan)H-Index: 12
view all 6 authors...
Abstract Long-acting injectable (LAI) antipsychotics have been developed to prevent symptom relapse in patients with schizophrenia; relapse has a detrimental clinical impact and high social burden. However, data on treatment continuation rates of LAI antipsychotics are inconsistent, primarily because of study design; limited data exist for patients taking oral psychotropic medications taken along with LAI antipsychotics, and factors related to LAI antipsychotics treatment discontinuation. Patien...
Source
Jun 20, 2019·Psychopharmacology Bulletin
#1Nicola PoloniH-Index: 12
#2Marta IelminiH-Index: 8
Last. Camilla CallegariH-Index: 14
view all 7 authors...
: Despite mixed results found in literature, long-acting injectable antipsychotics (LAIs) should offer better efficacy and tolerability, compared to oral antipsychotics due to improved adherence and more stable pharmacokinetics. From this perspective, authors evaluated 153 patients, diagnosed with Schizophrenia Spectrum Disorder and residing in the province of Varese (Italy), in order to compare oral antipsychotics' and LAIs' efficacy in terms of accesses to emergency room, number and length of ...
Feb 12, 2019·European Neuropsychopharmacology4.60
#1Isabella Pacchiarotti (University of Barcelona)H-Index: 32
#2Jari Tiihonen (University of Eastern Finland)H-Index: 90
Last. Eduard Vieta (University of Barcelona)H-Index: 141
view all 9 authors...
Abstract Long-Acting Injectable Antipsychotics (LAIs) are used to overcome non-compliance in psychoses, mainly schizophrenia spectrum disorders. We aimed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder (BD) and/or Schizoaffective Disorder (SAD). We searched six databases from inception to 28-March-2018, using the strategy: long-acting antipsychotics AND (bipolar disorder OR schizoaffective disorder OR mania OR manic OR...
Source
123456789
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.